These long-lived IL-2 fusion proteins have the potential to improve IL-2 immunotherapy in conditions where Proleukin has already been shown to provide benefit, GVHD and hepatitis C-induced vasculitis [20–22], as well as other inflammatory and autoimmune conditions. Here, IL2 is linked to graft versus host disease.